Data from 10 therapies across 10 types of cancer mechanisms of action highlighting Pfizer’s cutting-edge approach, expertise in precision medicine and work in immunotherapy combinations, will be presented present at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, May 31-June 4, 2019.
“The data presented at this year’s ASCO showcase our continued commitment to follow the science, whether it’s expanding our approved medicines for breast and prostate cancers into new populations and lines of therapy, or exploring the important role of biomarkers and immunotherapy combinations,” noted Dany Habr, M.D., Chief Medical Officer, Pfizer Oncology.
“We look forward to both sharing our exciting data in these and other tumor types, as well as connecting with our research partners to determine how we can continue to work collaboratively to bring transformative therapies to our cancer patients.”
The research to be presented includes new insights on Pfizer’s marketed therapies, including palbociclib (Ibrance®), enzalutamide (Xtandi®), talazoparib (Talzenna®). In addition to these treatments, Pfizer will present real-world data on the use of palbociclib for the treatment of men with metastatic breast cancer (MBC), a disease that may occur in men at any age, but it usually occurs in men between 60 and 70 years of age and makes up less than 1% of all cases of breast cancer.
“At this year’s ASCO, I am particularly excited that we’ll share data from new initiatives such as the oral presentation of talazoparib in breast cancer or other solid tumors. This builds on a productive year with the approval of four new oncology treatments, three biosimilars and three new indications, including one based on real-world evidence,” noted Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.
“We are proud to have one of the broadest oncology portfolios in the industry, and a research philosophy that puts patients first, embraces new approaches and showcases innovative thinking.”
Among the key Pfizer-sponsored, investigator-sponsored and collaborative research abstracts leveraging the depth of the company’s scientific advances include:
- A poster presentation on real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy (Abstract 1055).
- An external investigator-sponsored oral presentation on a Phase II trial examining talazoparib beyond BRCA, specifically as monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes (Investigator-sponsored abstract 3006).
- Biomarker analyses from the JAVELIN Renal 101 clinical trial that studied avelumab (Bavencio® ) plus axitinib (Inlyta®) vs. sunitinib (Sutent®) in advanced renal cell carcinoma (aRCC) (Abstract 101). 
- An external collaborative research presentation on genomic markers of early progression on fulvestrant with or without palbociclib for ER+ advanced breast cancer in the PALOMA-3 trial (Collaborative research abstract 1010). 
 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) – NCT02684006
 Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) – NCT01942135